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Brachial cuff blood pressure (BP) is clinically important, but may be an inaccurate substitute 
for central BP. Many non-invasive devices have been developed that purport to estimate 
central BP from peripheral artery sites, yet with no standardized guidelines; the accuracy 
testing of these new devices has not been undertaken in a uniform fashion with comparable 
protocols. This is an abridged paper describing the recommendations reached by an 
international task force convened to identify issues that need to be addressed and reach 
consensus relating to methods for assessing and reporting the accuracy (validation) of central 
BP devices. The recommendations are endorsed by the Association for Research into Arterial 
Structure and Physiology (ARTERY) Society, as well as the European Society of 
Hypertension (ESH) Working Group on Arterial Structure and Function, and the ESH 
Working Group on Blood Pressure Monitoring and Cardiovascular Variability. 
 





The original Riva-Rocci method to measure blood pressure (BP) using a cuff at the upper arm 
assumed the pressure obtained by this technique was a good proxy for central aortic BP.1, 2 The 
clinical (prognostic) importance of brachial cuff BP is undeniable for both the assessment of 
cardiovascular risk associated with elevated BP and the benefits of treatment-induced BP 
reduction.3 However, it is also generally appreciated that peripheral artery systolic BP (SBP; 
brachial or radial artery) may be an inaccurate substitute for central SBP.4 This has been 
reported in human studies using intra-arterial catheterization of peripheral and central arteries.5-
8 There may also be a discrepancy between peripheral and central BP responses to vasoactive 
drugs.9 These findings are corroborated in larger studies using non-invasive central aortic BP 
methods,10-13 and, while yet to be fully adopted in clinical practice, an independent prognostic 
value of central BP has been demonstrated.14-16 Altogether, there is a growing interest among 
clinicians toward improving risk estimates by using devices that provide more accurate 
measures of central aortic BP than those provided by current brachial cuff BP methods.  
 Many non-invasive devices have been developed that purport to estimate central BP 
from different peripheral artery sites (e.g. radial, brachial, carotid arteries) using different 
principles of recording the pressure or surrogate signals (e.g. applanation tonometry, 
oscillometry, ultrasound or magnetic resonance imaging) and different calibration methods to 
derive central BP. Since upper arm cuff-based devices to estimate central BP are more 
clinically appealing, in recent years several companies have developed such devices using a 
variety of techniques (e.g. oscillometric sub-diastolic or supra-systolic waveform analysis with 
generalized transfer functions), which employ a variety of signal processing steps to estimate 
central BP from peripheral signals.17, 18 Yet, with no standardized guidelines,17 the accuracy 




uniform fashion with comparable protocols, emphasizing the need for guidance in this field.19-
22 An international task force was convened to address this situation. 
Task force aims 
1. To identify issues that need to be addressed and reach consensus relating to methods for 
assessing and reporting the accuracy of central BP devices. 
2. To provide recommendations regarding appropriate protocols to assess and report the 
evaluation of accuracy (validation) of central BP devices. 
The full report of the task force was recently published23 and in this abridged version, the 
majority of information is presented in summary format within Tables. Table 1 gives a glossary 
of terms and a summary of issues and recommendations is provided in Table 2. A summary of 
differences between device types in comparison to intra-arterial brachial and central aortic BP 
are presented in Figure 1. 
Validation protocol requirements 
Several scientific bodies have developed validation protocols for non-invasive 
peripheral BP monitors,24-29 yet they differ on procedural features such as sample size and 
selection criteria, number of assessment phases, acceptable margin of error, BP range and 
pass/fail criteria.30 A ‘universal’ brachial BP validation protocol is under development through 
collaboration of the American Association for the Advancement of Medical Instrumentation 
(AAMI), the International Organization for Standardisation (ISO) and the ESH Working Group 
on Blood Pressure Monitoring and Cardiovascular Variability, and projected to be in effect in 
2018. This harmonised protocol is expected to inform many aspects of central BP validation 
protocols that equally apply to brachial BP (e.g. age, gender, BP range), but an internationally 
accepted central BP protocol directed by regulatory authorities is still required, as distinct from 




Recommendations focus on central BP specific protocol requirements, with some 
relevant features drawn from existing validation guidelines.24-26 For unambiguous 
interpretation of requirements, facets of the protocol have been listed in terms of “must,” 
“should” and “may.”  “Must” indicates a necessary component for highest quality, “should” 
indicates a strong recommendation, but may not be the only way that the component can be 
achieved, and “may” is used to provide further guidance. Protocol requirements are 
summarised in Table 3 as a pro-forma guide for investigators. Less attention is given to 
protocol features equally relevant to brachial BP (i.e. sample characteristics, results reporting 
and pass criteria) but some proposed direction is also provided based on existing guidelines24-
26 for interim guidance (and to highlight outstanding issues) prior to development of an 
accepted international central BP validation protocol. A list of issues in need of resolution in 
the future development of such a protocol is provided in Table 4.  
Sample characteristics. A sample size of at least n=85 adults is proposed based on brachial BP 
validation protocols and the requirement to detect a mean difference of 5 mmHg (standard 
deviation (Sd) of the difference 8 mmHg) with an estimated power of >99 % (two-sided alpha 
of 5%), as currently proposed by the AAMI standard. Nevertheless, invasive BP measures 
during clinical procedures face additional constraints that can increase BP variability, such as 
selective patient characteristics and limited time for repeat measurements. Thus, a definitive 
sample size based on robust statistical methods is still needed. If devices are to be used in 
paediatric age groups, then wherever possible, accuracy should be tested separately in those 
groups and not extrapolated from adults. Participants should have a sex distribution of at least 
30% male and female and in sinus rhythm unless the device is being tested for accuracy during 
arrhythmias.25 In keeping with all other brachial cuff BP validation guidelines, devices should 
be tested over a range of BP. An indicative range for invasive central SBP may be ≤100 mmHg 




the indicative range for invasive central DBP may be ≤60 mmHg (≥5% of readings), ≥85 
mmHg (≥20% of readings) and ≥100 mmHg (≥5% of readings).24 Device accuracy should also 
be tested across a range of heart rates (i.e. 60 to 100 bpm), because heart rate influences aortic 
stiffness and SBP amplification.31, 32 Exact criteria for BP and heart rate ranges needs to be 
resolved. Unless testing device performance in specific cardiac or respiratory diseases, it 
should be noted that subjects with the following conditions have a higher likelihood of 
measurement error due to abnormal haemodynamics: severe valvular stenosis or regurgitation, 
severely impaired left ventricular systolic function, atrial fibrillation, constrictive pericarditis, 
pericardial tamponade, restrictive cardiomyopathy or severe pulmonary disease. 
Statistical requirements. Beyond the reporting of details already mentioned, description of 
subjects must be presented and should include basic demographics (age, sex, ethnicity, body 
mass index), medications and clinical conditions including outcome of coronary catheterization 
procedure. Comparison between non-invasive and reference BP’s must report mean difference, 
Sd of the mean difference, and limits of agreement (LOA), illustrated by modified Bland-
Altman plots33 in which the mean of measurements is replaced by the reference catheter 
measurement. Scatter plots of the measures obtained with the non-invasive device (on Y axis) 
versus the reference method (on X axis), with the line of equality, may also be provided for 
descriptive purposes. Non-uniformity of Sd across the range of measurement or evidence of 
non-constant bias (e.g. increasing difference between measures with increasing values) must 
be visually checked on the Bland-Altman plots. An increase in variability of the differences as 
the magnitude of the measurement increases can be dealt with by log transformation of both 
measurements before analysis and the LOA derived from log transformed data should be 
reported after back-transformation (and thus expressed as ratios of the actual measurements). 
When log transformations do not solve the problem of a relationship between the difference 




with preference for the latter (for details see33). Absolute BP differences from the reference 
should be presented as a clinically meaningful illustration of the results but without a pass/fail 
criteria.24 The proposed pass criteria is if the device has a mean difference of ≤5 mmHg with 
Sd ≤8 mmHg compared with the reference, based on the magnitude of minimum tolerable error 
and frequency,24 but also recognizing this is a feature requiring resolution in future guidelines. 
Conclusions and future directions 
A major reason for producing this document to improve device validity has been the ongoing 
controversy over whether central BP adds prognostic value to that from routine brachial cuff 
BP. A recent Framingham paper found no additional value,34 while two systematic reviews not 
including those data came to opposite conclusions.14, 35 For unfamiliar readers, an 
accompanying editorial addresses the issues.36 A number of perceived deficits relating to both 
brachial and central BP measurement have been brought to attention in this current paper, and 
accordingly some points of intent require additional explanation. Firstly, despite the premise 
of clinical brachial BP measurement being based on essentially inaccurate cuff measures, 
brachial BP is still important and regarded as the clinical standard. This document should not 
be interpreted as challenging the clinical utility of brachial BP measurement, nor its value in 
hypertension management. Similarly, this document does not seek to undermine the potential 
clinical use of currently available non-invasive central BP devices that have not undergone the 
validation procedures recommended in this document, but have already proven to provide 
measurement of physiological (e.g. vascular ageing)37 or prognostic significance. Nevertheless, 
with the advent of “precision medicine,” clinical decisions are expected to be refined and 
improved by using more accurate BP monitors into the future, whether brachial or central BP, 
and this is a key research need. Additional guidance on central BP validation protocols is keenly 
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Figure 1. Illustration of the differences in systolic (SBP) and diastolic (DBP) blood pressure 
(BP) between intra-arterial brachial and central BP, brachial cuff BP and non-invasive central 
BP devices Types I and II (BP ranges of different methods represented by the double arrows). 
Red shaded area A, represents the true (intra-arterial) level of central-to-brachial SBP 
amplification, and red shaded area B represents the non-invasive estimated central-to-brachial 
SBP amplification (A and B may be similar in magnitude). The non-invasive central SBP 
estimated using central BP device Type II may be higher than non-invasive brachial cuff 
SBP, but this is due to underestimation of true (intra-arterial) brachial SBP with the cuff 
device and, therefore, does not reflect physiological amplification. The hatched areas denote 




Table 1. Glossary of terms. 
Intra-arterial (invasive) 
blood pressure 
Direct measurement of blood pressure within the artery 
using an in-dwelling catheter-based pressure transducer. 
Peripheral (non-invasive) 
blood pressure 
Blood pressure at a site distal from the aorta. This most 
often refers to brachial or radial artery blood pressure, 
but for the purpose of this paper also includes carotid 
blood pressure even though local derivation is regarded 
as a surrogate of central blood pressure. 
Central (aortic) blood 
pressure 
Blood pressure in the proximal ascending aorta. 
Systolic blood pressure 
amplification 
The increase in systolic blood pressure from proximal to 
peripheral arterial vessels (e.g. aorta-to-brachial, or 
brachial-to-radial arteries). 
Transfer function Signal processing step to estimate central blood pressure 
waveforms from peripherally recorded waveforms. 









1. Disparity of non-invasive central BP devices 
as to what is being measured 
Device manufacturers should clearly state the purported measurement 
function of their device. These can be broadly categorized into two types 
based on function: Type I – estimates central BP relative to measured 
brachial BP; Type II – estimates intra-arterial central BP.  
Both function types may be available within a single device. 
2. Calibration of peripheral artery signals 
using brachial cuff BP 
To achieve accurate non-invasive assessment of true central BP, more 
accurate non-invasive estimates of intra-arterial brachial BP are needed. 
Establishing more rigorous accuracy criteria for brachial BP is desirable. 
Current evidence suggests that calibration with MAP and DBP may provide 
a more accurate assessment of central BP than calibration with SBP and 
DBP. 
3. Disparity in validation standards The reference standard against which device accuracy of central BP estimation 
is gauged should be intra-arterial catheter in the ascending aorta. Details of the 
calibration method should be provided. If the brachial BP waveform 
undergoes recalibration to produce a ‘new’ brachial BP, then the recalibrated 
brachial BP values (and the method to derive them) should also be provided 
so that the level of estimated aorta-to-brachial systolic BP amplification can 
be gauged. 
4. Limitations in performing invasive 
validation studies 
In future, it may be reasonable to use non-invasive central BP devices as 





Table 3. Summary of central blood pressure (BP) device validation protocol components and requirements. 
Protocol Section Protocol Item Protocol Requirement Protocol Undertaken  
(circle yes/no ….comment) 
Study setting Isolated room without 
disturbing influences. 
Should YES  
NO…………………………………………… 
Non-invasive central BP 
device measurement 
standards 
List manufacturer, model, 
software version, operating 
principles, signal processing 
step/s, calibration processes. 
Must YES  
NO…………………………………………… 
 Time for BP measures; time 
points of brachial BP and 
central BP; cuff deflation 
speed. 
Should YES  
NO…………………………………………… 
 Define and use appropriate 
cuff size.  
Must YES  
NO…………………………………………… 
 Dimensions of inflatable 
bladder for all cuff sizes 
available; process to 
determine cuff size. 
Should YES  
NO…………………………………………… 
 Process of familiarisation with 
equipment. 
Should YES  
NO…………………………………………… 
 Separate validation studies for 
additional or optional features 
or functions. 





 Process/s of quality control; 
process used to delineate 
acceptable quality; number of 
unacceptable readings; 
reason/s for exclusion. 
Must YES  
NO…………………………………………… 
Invasive (intra-arterial) 
central BP reference standard 
Micromanometer-tipped 
catheter used if minor 
inflection points to be 
identified. 
Should YES  
NO…………………………………………… 
 Full description of catheter; 
frequency response and 
handling procedures. 
Must YES  
NO…………………………………………… 
 Performance comparison of 
fluid filled catheter with 
micromanometer-tipped 
catheter. 
May YES  
NO…………………………………………… 
Data acquisition at rest Period of undisturbed rest; 
medications used. 
Should YES  
NO…………………………………………… 
 No talking. Free from acute 
hemodynamic interventions 
Must YES  
NO…………………………………………… 
 Test device compared with 
reference over time-period 
matching the test device 
deflation cycle; recorded 
under stable conditions. 





 Complete description of 
protocol; time interval 
between test device and 
reference measures. 
Must YES  
NO…………………………………………… 
Data acquisition at BP 
intervention 
Hemodynamic change from 
resting state. 
May YES  
NO…………………………………………… 
 Description of the 
intervention procedure. 
Must YES  
NO…………………………………………… 
SBP, systolic BP; DBP, diastolic BP. Complete details of protocol components and requirements are contained within the body text. Must, 
necessary component for highest quality; Should, strong recommendation, but probably not the only way that the component can be achieved; 




Table 4. Summary list of issues for consideration in development of an internationally accepted central blood pressure (BP) validation protocol. 
Validation protocol features Comments 
Reference method  
Non-invasive reference standard. What criteria needed to satisfy for an acceptable non-invasive alternative to the invasive 
method which restricts study sample characteristics? 
Error  
Minimum standard. What is the magnitude of the minimum acceptable error and its frequency based on the 
invasive reference standard? 
Study sample  
Definition of general population sample.  Which populations should be considered as special as there may be different device 
measurement accuracy from the general population, and therefore require separate validation? 
Minimum sample size for a general 
population study. 
Based on the reference method for an acceptable statistical risk of false positive and negative 
results.  
Sample size for validations in special 
groups. 
To be defined after a successful study in the general population has been completed. 
Sex and age distribution. Representation of males and females, adolescents, young and middle aged adults and elderly. 
BP and heart rate range criteria. Based on reference central BP measurements and heart rate during the procedure? 
Cuff size.  Minimum number of subjects investigated per different cuff size, or number of different cuffs 
to be studied in a single study? 
Exclusion criteria. On the basis of increased reference BP variation within individual validation procedures or 
clinical conditions. 
Procedural   
Number of measurements. Procedure for the number of reference and test BP measurements in a validation session. 
Comparison with reference. How to compare when operating characteristics differ between reference (i.e. beat-to-beat) and 
non-invasive test devices (i.e. averaging over seconds to minutes) and influence of respiratory 
variation and arrhythmias? 
Reporting   
Data and pass criteria. What data, statistics and study features to be reported? What pass/fail criteria?  
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